---
document_datetime: 2025-11-23 08:09:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/exviera.html
document_name: exviera.html
version: success
processing_time: 0.1305549
conversion_datetime: 2025-12-25 11:42:02.88903
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Exviera

[RSS](/en/individual-human-medicine.xml/65589)

##### Withdrawn

This medicine's authorisation has been withdrawn

dasabuvir

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Exviera](#news-on)
- [More information on Exviera](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 25 September 2024, the European Commission withdrew the marketing authorisation for Exviera (dasabuvir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AbbVie Deutschland GmbH &amp; Co. KG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Exviera was granted marketing authorisation in the EU on 15 January 2015 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019.

The European Public Assessment Report (EPAR) for Exviera is updated to indicate that the marketing authorisation is no longer valid.

Exviera : EPAR - Summary for the public

English (EN) (166.74 KB - PDF)

**First published:** 12/02/2015

**Last updated:** 01/10/2024

[View](/en/documents/overview/exviera-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-187)

български (BG) (231.25 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/bg/documents/overview/exviera-epar-summary-public_bg.pdf)

español (ES) (163.05 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/es/documents/overview/exviera-epar-summary-public_es.pdf)

čeština (CS) (208.15 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/cs/documents/overview/exviera-epar-summary-public_cs.pdf)

dansk (DA) (163.63 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/da/documents/overview/exviera-epar-summary-public_da.pdf)

Deutsch (DE) (173.7 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/de/documents/overview/exviera-epar-summary-public_de.pdf)

eesti keel (ET) (155.02 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/et/documents/overview/exviera-epar-summary-public_et.pdf)

ελληνικά (EL) (240.91 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/el/documents/overview/exviera-epar-summary-public_el.pdf)

français (FR) (165.71 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fr/documents/overview/exviera-epar-summary-public_fr.pdf)

hrvatski (HR) (196.64 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hr/documents/overview/exviera-epar-summary-public_hr.pdf)

italiano (IT) (162.89 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/it/documents/overview/exviera-epar-summary-public_it.pdf)

latviešu valoda (LV) (206.85 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lv/documents/overview/exviera-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (202.3 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lt/documents/overview/exviera-epar-summary-public_lt.pdf)

magyar (HU) (192.42 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hu/documents/overview/exviera-epar-summary-public_hu.pdf)

Malti (MT) (215.21 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/mt/documents/overview/exviera-epar-summary-public_mt.pdf)

Nederlands (NL) (167.51 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/nl/documents/overview/exviera-epar-summary-public_nl.pdf)

polski (PL) (209.13 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pl/documents/overview/exviera-epar-summary-public_pl.pdf)

português (PT) (165.7 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pt/documents/overview/exviera-epar-summary-public_pt.pdf)

română (RO) (208.13 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/ro/documents/overview/exviera-epar-summary-public_ro.pdf)

slovenčina (SK) (203.12 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sk/documents/overview/exviera-epar-summary-public_sk.pdf)

slovenščina (SL) (194.21 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sl/documents/overview/exviera-epar-summary-public_sl.pdf)

Suomi (FI) (160.02 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fi/documents/overview/exviera-epar-summary-public_fi.pdf)

svenska (SV) (162.81 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sv/documents/overview/exviera-epar-summary-public_sv.pdf)

Exviera : EPAR - Risk-management-plan summary

English (EN) (219.92 KB - PDF)

**First published:** 12/02/2015

**Last updated:** 01/10/2024

[View](/en/documents/rmp-summary/exviera-epar-risk-management-plan-summary_en.pdf)

## Product information

Exviera : EPAR - Product Information

English (EN) (2.11 MB - PDF)

**First published:** 12/02/2015

**Last updated:** 01/10/2024

[View](/en/documents/product-information/exviera-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-855)

български (BG) (2.23 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/bg/documents/product-information/exviera-epar-product-information_bg.pdf)

español (ES) (2.3 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/es/documents/product-information/exviera-epar-product-information_es.pdf)

čeština (CS) (2.32 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/cs/documents/product-information/exviera-epar-product-information_cs.pdf)

dansk (DA) (2.16 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/da/documents/product-information/exviera-epar-product-information_da.pdf)

Deutsch (DE) (2.24 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/de/documents/product-information/exviera-epar-product-information_de.pdf)

eesti keel (ET) (2.14 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/et/documents/product-information/exviera-epar-product-information_et.pdf)

ελληνικά (EL) (2.56 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/el/documents/product-information/exviera-epar-product-information_el.pdf)

français (FR) (1.86 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fr/documents/product-information/exviera-epar-product-information_fr.pdf)

hrvatski (HR) (2.28 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hr/documents/product-information/exviera-epar-product-information_hr.pdf)

íslenska (IS) (2.25 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/is/documents/product-information/exviera-epar-product-information_is.pdf)

italiano (IT) (2.21 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/it/documents/product-information/exviera-epar-product-information_it.pdf)

latviešu valoda (LV) (2.01 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lv/documents/product-information/exviera-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.37 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lt/documents/product-information/exviera-epar-product-information_lt.pdf)

magyar (HU) (2.3 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hu/documents/product-information/exviera-epar-product-information_hu.pdf)

Malti (MT) (2.45 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/mt/documents/product-information/exviera-epar-product-information_mt.pdf)

Nederlands (NL) (2.26 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/nl/documents/product-information/exviera-epar-product-information_nl.pdf)

norsk (NO) (2.17 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/no/documents/product-information/exviera-epar-product-information_no.pdf)

polski (PL) (2.38 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pl/documents/product-information/exviera-epar-product-information_pl.pdf)

português (PT) (1.8 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pt/documents/product-information/exviera-epar-product-information_pt.pdf)

română (RO) (2.55 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/ro/documents/product-information/exviera-epar-product-information_ro.pdf)

slovenčina (SK) (2.3 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sk/documents/product-information/exviera-epar-product-information_sk.pdf)

slovenščina (SL) (2.17 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sl/documents/product-information/exviera-epar-product-information_sl.pdf)

Suomi (FI) (2.28 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fi/documents/product-information/exviera-epar-product-information_fi.pdf)

svenska (SV) (2.16 MB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sv/documents/product-information/exviera-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS2430 12/08/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Exviera : EPAR - All Authorised presentations

English (EN) (41.65 KB - PDF)

**First published:** 12/02/2015

**Last updated:** 01/10/2024

[View](/en/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-438)

български (BG) (64.85 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/bg/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.23 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/es/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.22 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/cs/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.23 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/da/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.03 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/de/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.43 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/et/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.39 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/el/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_el.pdf)

français (FR) (43.14 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fr/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.03 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hr/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.3 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/is/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_is.pdf)

italiano (IT) (43.88 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/it/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.33 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lv/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.82 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/lt/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.99 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/hu/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.86 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/mt/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.64 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/nl/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.13 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/no/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.76 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pl/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.72 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/pt/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.44 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/ro/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.08 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sk/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.2 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sl/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.1 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/fi/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.76 KB - PDF)

**First published:**

12/02/2015

**Last updated:**

01/10/2024

[View](/sv/documents/all-authorised-presentations/exviera-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Exviera Active substance dasabuvir sodium International non-proprietary name (INN) or common name dasabuvir Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP09

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

## Authorisation details

EMA product number EMEA/H/C/003837

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

AbbVie Ltd

Vanwall Business Park, Vanwall Road Maidenhead Berkshire SL6 4UB United Kingdom

Opinion adopted 20/11/2004 Marketing authorisation issued 14/01/2015 Withdrawal of marketing authorisation 25/09/2024 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Exviera : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.22 MB - PDF)

**First published:** 30/09/2015

**Last updated:** 01/10/2024

[View](/en/documents/procedural-steps-after/exviera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Exviera : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (136.09 KB - PDF)

**First published:** 07/07/2022

**Last updated:** 01/10/2024

[View](/en/documents/scientific-conclusion/exviera-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Exviera-H-C-3837-P46-0021 : EPAR - Assessment report

Adopted

Reference Number: EMA/92477/2021

English (EN) (544.96 KB - PDF)

**First published:** 01/09/2021

**Last updated:** 01/10/2024

[View](/en/documents/variation-report/exviera-h-c-3837-p46-0021-epar-assessment-report_en.pdf)

Exviera-H-C-3837-P46-0019 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/105448/2019

English (EN) (1.94 MB - PDF)

**First published:** 30/08/2021

**Last updated:** 01/10/2024

[View](/en/documents/variation-report/exviera-h-c-3837-p46-0019-epar-assessment-report_en.pdf)

Exviera-H-C-PSUSA-10363-201801 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/633869/2018

English (EN) (115.58 KB - PDF)

**First published:** 12/12/2018

**Last updated:** 01/10/2024

[View](/en/documents/scientific-conclusion/exviera-h-c-psusa-10363-201801-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Exviera-H-C-3837-A20-1438 : EPAR - Assessment report - Article 20

Reference Number: EMA/103226/2017

English (EN) (1.19 MB - PDF)

**First published:** 13/03/2017

**Last updated:** 01/10/2024

[View](/en/documents/variation-report/exviera-h-c-3837-a20-1438-epar-assessment-report-article-20_en.pdf)

Exviera-H-C-3837-A20-0017 : EPAR - Scientific Conclusion

English (EN) (219.64 KB - PDF)

**First published:** 13/03/2017

**Last updated:** 01/10/2024

[View](/en/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-586)

български (BG) (340.62 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/bg/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_bg.pdf)

español (ES) (216.72 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/es/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_es.pdf)

čeština (CS) (282.49 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/cs/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_cs.pdf)

dansk (DA) (225.38 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/da/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (246.2 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/de/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (214.88 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/et/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (375.22 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/el/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_el.pdf)

français (FR) (219.59 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/fr/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (295.32 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/hr/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_hr.pdf)

italiano (IT) (232.47 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/it/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (334.56 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/lv/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (299.54 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/lt/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_lt.pdf)

magyar (HU) (247.73 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/hu/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_hu.pdf)

Malti (MT) (315.95 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/mt/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (236.87 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/nl/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_nl.pdf)

polski (PL) (288.39 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/pl/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_pl.pdf)

português (PT) (221.47 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/pt/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_pt.pdf)

română (RO) (304.34 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/ro/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (269.89 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/sk/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (306.08 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/sl/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (221.13 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/fi/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_fi.pdf)

svenska (SV) (222.65 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

01/10/2024

[View](/sv/documents/scientific-conclusion/exviera-h-c-3837-a20-0017-epar-scientific-conclusion_sv.pdf)

Exviera-H-C-PSUSA-00010363-201507 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/289707/2016

English (EN) (115.82 KB - PDF)

**First published:** 02/05/2016

**Last updated:** 01/10/2024

[View](/en/documents/scientific-conclusion/exviera-h-c-psusa-00010363-201507-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Exviera : EPAR - Public assessment report

Adopted

Reference Number: EMA/768319/2014

English (EN) (6.55 MB - PDF)

**First published:** 12/02/2015

**Last updated:** 01/10/2024

[View](/en/documents/assessment-report/exviera-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Exviera

Adopted

Reference Number: EMA/CHMP/688227/2014

English (EN) (136.15 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 01/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-exviera_en.pdf)

#### News on Exviera

[Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B](/en/news/direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b) 16/12/2016

[PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C](/en/news/prac-warns-risk-hepatitis-b-re-activation-direct-acting-antivirals-hepatitis-c) 02/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

[Two new medicines recommended for the treatment of chronic hepatitis C](/en/news/two-new-medicines-recommended-treatment-chronic-hepatitis-c) 21/11/2014

#### More information on Exviera

- [EMEA-001439-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001439-pip01-13-m03)
- [Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free) - referral](/en/medicines/human/referrals/direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free)
- [A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/44706)

**This page was last updated on** 01/10/2024

## Share this page

[Back to top](#main-content)